(371 days)
P010002
Not Found
No
The device description and performance studies focus on the chemical composition and physical properties of a tissue adhesive, with no mention of AI or ML technologies.
No
The device is a tissue adhesive used to close skin incisions and lacerations, which is a treatment for a condition, but not a therapy in itself.
No
The device is a tissue adhesive intended for closing skin incisions and lacerations, which is a therapeutic function, not a diagnostic one.
No
The device description clearly states it is a sterile, topical tissue adhesive containing n-butyl-2-cyanoacrylate and is supplied in an ampoule. This indicates a physical, chemical product, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to perform tests on samples taken from the human body (like blood, urine, tissue) to provide information about a person's health. These tests are performed outside of the body.
- GluStitch Twist Function: The description clearly states that GluStitch Twist Tissue Adhesive is intended for "topical skin incisions and trauma-induced lacerations." It is applied directly to the body to close wounds.
- No Sample Testing: There is no mention of this device being used to analyze samples taken from a patient.
Therefore, GluStitch Twist Tissue Adhesive is a medical device used for wound closure, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
GluStitch® Twist Tissue Adhesive is intended for the topical closure of surgical skin incisions and trauma-induced lacerations in areas of low skin tension that are simple, thoroughly-cleansed, and have easily approximated skin edges. GluStitch® Twist may be used in conjunction with, but not in place of, deep dermal stitches.
Product codes
MPN
Device Description
GluStitch Twist Tissue Adhesive is a sterile, topical tissue adhesive containing n-butyl-2-cyanoacrylate. GluStitch Twist Tissue Adhesive is supplied in a single patient use, twist-and-use ampoule that contains at least 0.5g of liquid tissue adhesive.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
skin
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The following comparative testing demonstrated substantially equivalent performance between GluStitch Twist Tissue Adhesive and Indermil Tissue Adhesive:
- Tensile strength (ASTM F2255-05, F2258-05, F2458-05)
- Set (polymerization) time
- Heat of polymerization
- Viscosity
- Hydrolytic degradation
- Applicator expression force
- Chemical analysis
In vivo assessment of incision closure was conducted in swine, the objective of which was a 15 day GLP study to demonstrate substantial equivalence of the safety and equivalence of GluStitch Twist Tissue Adhesive to Indermil Tissue Adhesive in closing incisions. Primary safety objective evaluated the incidence of chemical burn, infection, and the histopathologic evidence of the tissue adhesive adversely affecting incision healing. Study parameters were evaluated at 4, 9 and 14 days post-closure, corresponding to Study Days 5, 10 and 15 respectively. The results demonstrate substantial equivalence of the safety and efficacy of GluStitch Twist Tissue Adhesive in relation to Indermil Tissue Adhesive for incision closure in an in vivo swine model.
Key Metrics
Not Found
Predicate Device(s)
Indermil® Tissue Adhesive (P010002)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.4010 Tissue adhesive.
(a)
Tissue adhesive for the topical approximation of skin —(1)Identification. A tissue adhesive for the topical approximation of skin is a device intended for topical closure of surgical incisions, including laparoscopic incisions, and simple traumatic lacerations that have easily approximated skin edges. Tissue adhesives for the topical approximation of skin may be used in conjunction with, but not in place of, deep dermal stitches.(2)
Classification. Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: “Tissue Adhesive for the Topical Approximation of Skin.” See § 878.1(e) of this chapter for the availability of this guidance document.(b)
Tissue adhesive for non-topical use —(1)Identification. A tissue adhesive for non-topical use, including adhesives intended for use in the embolization of brain arteriovenous malformation or for use in ophthalmic surgery, is a device used for adhesion of internal tissues and vessels.(2)
Classification. Class III (premarket approval). As of May 28, 1976, an approval under section 515 of the act is required before this device may be commercially distributed. See § 878.3 of this chapter.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized image of an eagle with three human profiles incorporated into its design. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
January 14, 2016
GluStitch Incorporated Mr. Tim Robinson Regulatory and Clinical Quality Project Director Regulatory and Clinical Research Institute Incorporated 5353 Wayzata Boulevard. Suite 505 Minneapolis, Minnesota 55416
Re: K150032
Trade/Device Name: GluStitch® Twist Tissue Adhesive Regulation Number: 21 CFR 878.4010 Regulation Name: Tissue adhesive Regulatory Class: Class II Product Code: MPN Dated: January 8, 2015 Received: January 11, 2015
Dear Mr. Robinson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21
1
CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
David Krause -S
- for
Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K150032
Device Name GluStitch® Twist Tissue Adhesive
Indications for Use (Describe)
GluStitch® Twist Tissue Adhesive is intended for the topical skin incisions and trauma-induced lacerations in areas of low skin tension that are simple, thoroughly-cleansed, and have easily approximated skin edges. GluStitch® Twist may be used in conjunction with, but not in place of, deep dermal stitches.
| Type of Use (Select one or both, as applicable) |
|---|
| ☒ Prescription Use (Part 21 CFR 801 Subpart D) |
| ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows a logo with a purple square on the left, followed by the letters "GS" in black. To the right of the letters is a purple water droplet. The droplet has some white shapes inside of it, and it appears to be reflecting light.
GluStitch Inc.
www.glustitch.com ◎ Ph: (877) 940-2262 Fax: (877) 450-4000
510(K) SUMMARY
| Submitted by: | GluStitch, Inc. |
|---|---|
| Contact Person: | Don Blacklock |
| President | |
| GluStitch, Inc. | |
| 307-7188 Progress Way | |
| Delta BC V4G 1M6 | |
| Canada | |
| Tel: 800-667-2130 | |
| Fax: 604-940-0552 | |
| Email: blacklock@glustitch.com | |
| Date of Summary: | January 8, 2016 |
| Device Trade Name: | |
| Common or Usual Name: | |
| Classification Name: | |
| Class: | |
| Product Code: | GluStitch® Twist Tissue Adhesive |
| Topical Tissue Adhesive | |
| Tissue Adhesive (21 CFR 878.4010) | |
| II | |
| MPN | |
| Predicate Device(s): | Indermil® Tissue Adhesive (P010002) |
| Device Description: | GluStitch Twist Tissue Adhesive is a sterile, topical tissue |
| adhesive containing n-butyl-2-cyanoacrylate. GluStitch Twist | |
| Tissue Adhesive is supplied in a single patient use, twist-and- | |
| use ampoule that contains at least 0.5g of liquid tissue | |
| adhesive. | |
| Indication for Use: | GluStitch Twist Tissue Adhesive is intended for the topical |
| closure of surgical skin incisions and trauma-induced | |
| lacerations in areas of low skin tension that are simple, | |
| thoroughly-cleansed, and have easily approximated skin edges. | |
| GluStitch Twist may be used in conjunction with, but not in place | |
| of, deep dermal stitches. | |
| Technological | |
| Characteristics | |
| (compared to predicate): | The technological characteristics of the GluStitch Twist Tissue |
| Adhesive are equivalent in performance to the predicate device | |
| Indermil Tissue Adhesive (P010002). GluStitch Twist Tissue | |
| Adhesive has been shown to be substantially equivalent and | |
| has the same performance characteristic to the predicate | |
| devices through comparison to the Indication for Use, |
4
GluStitch Inc.
www.qlustitch.com @ Ph: (877) 940-2262 Fax: (877) 450-4000
formulation, technology, intended application, mechanism of action, and performance.
The GluStitch Twist Tissue Adhesive uses n-butyl-2cyanoacrylate technology to facilitate wound closure. It is supplied sterile, in single use applicators that are designed to deliver the adhesive to the wound, to bond to the skin edges to provide wound closure and to maintain wound approximation.
The main differences between GluStitch Twist Tissue Adhesive and Indermil Tissue Adhesive relate to a minor change to the formulation to allow stability after sterilization and addition of violet D & C Violet #2 for visibility purposes.
Substantial Equivalence Rationale:
GluStitch Twist Tissue Adhesive is substantially equivalent to Indermil Tissue Adhesive (P010002) with regard to Indication For Use, formulation, technology, intended application, mechanism of action and performance at achieving its intended use.
Performance Testing:
Biocompatibility
The biocompatibility tests conducted were for a "breached or compromised surface with prolonged contact duration of greater than 24 hours but less than 30 days". All of the testing was performed using Good Laboratory Practices (GLP).
| ISO 10993-5 | (2009) | Biological Evaluation of Medical
Devices, Part 5: Tests for in vitro
cytotoxicity |
|--------------|--------|------------------------------------------------------------------------------------------------------|
| ISO 10993-6 | (2007) | Biological Evaluation of Medical
Devices, Part 6: Tests for local
effects after implantation |
| ISO 10993-10 | (2010) | Biological Evaluation of Medical
Devices, Part 10: Tests for
irritation and skin sensitization |
Sterilization and Shelf Life
Sterilization validation testing indicates a Sterility Assurance Level of 10-6 (SAL 10-6) is obtained when GluStitch Twist Tissue Adhesive is subjected to 17.5 kGy of radiation. Real time and accelerated aging shelf life testing has been
conducted. The data from these studies support a 24 month shelf life.
5
GluStitch Inc.
www.glustitch.com ◎ Ph: (877) 940-2262 Fax: (877) 450-4000
Comparative Testing
The following comparative testing demonstrated substantially equivalent performance between GluStitch Twist Tissue Adhesive and Indermil Tissue Adhesive:
- Tensile strength (ASTM F2255-05, F2258-05, F2458-05) ■
- Set (polymerization) time ם
- ם Heat of polymerization
- ם Viscosity
- Hydrolytic degradation ■
- 트 Applicator expression force
- ם Chemical analysis
In vivo assessment of incision closure was conducted in swine, the objective of which was a 15 day GLP study to demonstrate substantial equivalence of the safety and equivalence of GluStitch Twist Tissue Adhesive to Indermil Tissue Adhesive in closing incisions. Primary safety objective evaluated the incidence of chemical burn, infection, and the histopathologic evidence of the tissue adhesive adversely affecting incision healing. Study parameters were evaluated at 4, 9 and 14 days post-closure, corresponding to Study Days 5, 10 and 15 respectively. The results demonstrate substantial equivalence of the safety and efficacy of GluStitch Twist Tissue Adhesive in relation to Indermil Tissue Adhesive for incision closure in an in vivo swine model.
Conclusion: Based on the non-clinical testing conducted, GluStitch Twist Tissue Adhesive is considered safe and effective when used as indicated. Performance testing has demonstrated GluStitch Twist is substantially equivalent to the legally marketed predicate device, Indermil Tissue Adhesive.